(lp0
S"Ionis Pharmaceuticals Inc. Doesn't Want to Sell Drugs  Motley Fool - 10 hours ago Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen, Celgene, Gilead Sciences, and Ionis Pharmaceuticals. The Motley Fool has the following options: short June 2017 $70 calls on GILD. The Motley&nbsp;..."
p1
aS'Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics Motley Fool - Mar 21, 2017 If you enjoy cutting-edge medicine, Ionis Pharmaceuticals Inc  and Juno Therapeutics Inc  are two biotech stocks that belong on your radar.'
p2
aS"Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money Motley Fool - Mar 1, 2017 Ionis Pharmaceuticals  reported fourth-quarter earnings on Tuesday. The biotech has two drugs on the market, but given Kynamro's low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December, most of&nbsp;..."
p3
aS"Company Update : Here's Why Ionis Pharmaceuticals Inc Shares ... Smarter Analyst - Feb 28, 2017 Ionis Pharmaceuticals Inc  reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments.Ionis Pharmaceuticals  Beats on Q4 Earnings - Yahoo FinanceIonis Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 03 - Equities.com"
p4
aS'Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen ... PR Newswire  - Mar 6, 2017 CARLSBAD, Calif. and CAMBRIDGE, Mass., March 6, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. , today announced that the pivotal Phase 3 APPROACH study of volanesorsen met its&nbsp;...Why Ionis Pharmaceuticals Rallied 12% in February - Motley FoolDigging Up the Facts on Ionis Pharmaceuticals, Inc.  - StockNewsJournal'
p5
aS'Why Ionis Pharmaceuticals Is Tumbling 10% Today Motley Fool - Mar 10, 2017 What happened. After highly regarded investment firm Goldman Sachs cut its rating on the company, Ionis Pharmaceuticals  shares dropped by more than 10% at 1:45 p.m. EST today.Analyst Activity  Goldman Sachs Group Inc Reiterates Neutral on Ionis ... - Market ExclusiveIonis Pharmaceuticals Inc  Stock Dips on Goldman Sachs Downgrade - Investorplace.com'
p6
aS'Reviewing the Numbers for Ionis Pharmaceuticals, Inc.  Rives Journal - 12 hours ago Individual investors might be studying multiple metrics in order to maximize returns. Ionis Pharmaceuticals, Inc.  presently has a Gross Margin  ratio of 0.379871.'
p7
aS"Goldman Sachs downgrade today creates a buying opportunity. Seeking Alpha - Mar 13, 2017 Long-term investors should stiff-arm today's Goldman Sachs downgrade of Ionis Pharmaceuticals  from Neutral to Sell because analyst Salveen Richter has ignored recent evidence exonerating the platform of alleged toxicity."
p8
aS'Institutional Investors Remain the Majority Holders of Company Stock: Ionis ... Midway Monitor - 8 hours ago Based on the lastest quarterly filings, institutions continue to be large stakeholders in Ionis Pharmaceuticals, Inc. .Buy, Sell or Hold? Analysts Approach: Ionis Pharmaceuticals, Inc. (IONS ... - The USA CommerceHot Stock Update: Ionis Pharmaceuticals, Inc.  - HugoPress'
p9
aS'IONIS PHARMACEUTICALS,INC.  Files An 8-K Other Events Market Exclusive - Mar 27, 2017 Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid -targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs.Ionis Pharma  Spinoff Akcea Therapeutics  Files IPO - StreetInsider.comAkcea Therapeutics Announces Three Additions to Board of Directors - Yahoo Finance'
p10
a.